Short summary

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare, indolent B-cell malignancy accounting for approximately 5% of all Hodgkin Lymphoma (HL) cases. First ilne treatment has varied and there is no gold standard for treatment of recurrent NLPHL. Research on NLPHL is limited due to the rarity of the disease.

With this study we hope to bring further knowledge about long-term toxicities and survivorship with different treatments for this rare disease.

Rationale

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare, indolent B-cell malignancy accounting for approximately 5% of all Hodgkin Lymphoma (HL) cases. Research on NLPHL is limited due to the rarity of the disease. Knowledge about the burden of long-term treatment related side effects such as secondary neoplasms, cardiovascular disease and reduced childbearing ability in this group of relatively young patients with an expected long lifetime is limited. To improve the management of NLPHL, and to distinguish between high-risk and standard-risk disease, more knowledge is needed to guide and standardize therapy. With this study we hope to bring further knowledge about long-term toxicities and survivorship with different treatments for this rare disease. With a large dataset, rarer side effects, both short- and long term, of the treatment can be captured.

Description of the cohort

Patients ≥ 16 years old with the diagnosis of NLPHL between the year 2000-2020 in Denmark.

Data and biological material

Data from the national lymphoma registry (LYFO) and data from patient journals.

Collaborating researchers and departments

All hematological departments in Denmark, that are involved in treatment with NLPHL